Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter 2025 (January 1, 2025 – March 31, 2025)
Reporting Date: May 7, 2025
Novo Nordisk reported strong first-quarter results driven by significant growth in its Obesity care segment, particularly Wegovy. However, the company lowered its full-year 2025 outlook due to lower-than-planned penetration of branded GLP-1 treatments in the US, attributed to the rapid expansion of compounded GLP-1s.
Key Financial Metrics
| Metric (DKK Million) | Q1 2025 | Q1 2024 | Growth (Reported) | Growth (CER*) |
|---|---|---|---|---|
| Net Sales | 78,087 | 65,349 | 19% | 18% |
| Operating Profit | 38,791 | 31,846 | 22% | 20% |
| Net Profit | 29,034 | 25,407 | 14% | N/A |
| Diluted EPS (DKK) | 6.53 | 5.68 | 15% | N/A |
| Free Cash Flow | 9,492 | 5,020 | 89% | N/A |
| Capital Expenditure (PP&E) | 13,422 | 8,474 | 58% | N/A |
| Operating Margin | 49.7% | 48.7% | +1.0 pp | N/A |
| Effective Tax Rate | 21.6% | 20.4% | +1.2 pp | N/A |
*CER: Constant Exchange Rates (average 2024)
Material Changes vs. Prior Period
- Obesity Care Surge: Sales increased by 67% (65% at CER) to DKK 18.4 billion, driven by Wegovy sales growth of 85% (83% at CER). International Obesity care sales grew 137% at CER.
- Diabetes Care: Sales grew 10% (8% at CER) to DKK 55.0 billion. GLP-1 diabetes sales grew 13% (11% at CER), while insulin sales grew 4% (3% at CER). Victoza sales declined 46% as the market shifts to once-weekly treatments.
- Geographic Performance: US Operations sales grew 20% (17% at CER), while International Operations grew 18% (19% at CER). Emerging Markets and APAC showed the highest growth rates at 24% and 25% at CER, respectively.
- Cost Structure: Cost of goods sold increased 30% due to amortization related to the Catalent acquisition and capacity expansion costs. Gross margin decreased to 83.5% from 84.8%.
- Financial Items: Net financial items turned to a loss of DKK 1.8 billion (vs. gain of DKK 72 million in Q1 2024) due to currency hedging losses and financing costs for the Catalent transaction.
Guidance, Outlook, and Risks
Updated 2025 Outlook
Management has revised its full-year 2025 expectations downward:
- Sales Growth: Now expected to be 13-21% at CER (previously 16-24%). Reported growth is expected to be ~3 percentage points lower than CER due to USD/DKK exchange rates.
- Operating Profit Growth: Now expected to be 16-24% at CER (previously 19-27%). Reported growth is expected to be ~5 percentage points lower than CER.
- Free Cash Flow: Revised to DKK 56-66 billion (previously DKK 75-85 billion).
- Capital Expenditure: Remains around DKK 65 billion.
Management Commentary & Risks
- Compounded GLP-1s: The primary headwind is the rapid expansion of compounded semaglutide in the US, which has impacted branded Wegovy penetration. The FDA removed semaglutide from the drug shortage list in February 2025, ending enforcement discretion for compounding pharmacies in April/May 2025.
- Supply Constraints: Periodic supply constraints and drug shortage notifications continue to impact certain products and geographies.
- R&D Milestones:
- CagriSema: REDEFINE 2 trial completed with 15.7% weight loss; regulatory filing expected Q1 2026.
- Oral Semaglutide 25mg: Submitted to US FDA for obesity indication.
- MASH: Once-weekly semaglutide 2.4mg submitted for EU/US approval (Priority Review granted in US).
- Legal: Novo Nordisk intervened in litigation challenging the FDA's resolution of the semaglutide shortage. The court denied a preliminary injunction for compounding organizations in April 2025.
Investor Verification Checklist
- US Market Dynamics: Verify the actual impact of the FDA's enforcement actions on compounded GLP-1s on Q2 and Q3 branded sales volumes.
- Supply Chain Capacity: Monitor updates on the integration of Catalent manufacturing sites and the timeline for resolving periodic supply constraints.
- Regulatory Approvals: Track the status of the oral semaglutide 25mg submission and the MASH indication for semaglutide 2.4mg.
- FX Exposure: Assess the sensitivity of the outlook to further depreciation of the USD against the DKK, which is expected to reduce reported growth by 3-5 percentage points.
- Capital Allocation: Confirm the dividend payout ratio remains near 50% of net profit given the high CAPEX requirements and reduced free cash flow guidance.